We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.89%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$74.4B
AUM Growth
+$7.26B
(+11%)
Cap. Flow
+$2.46B
Cap. Flow
% of AUM
3.31%
Top 10 Holdings %
Top 10 Hldgs %
19.47%
Holding
3,107
New
25
Increased
2,535
Reduced
421
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$141M |
| 2 |
Apple
AAPL
|
+$117M |
| 3 |
iShares MSCI ACWI ex US ETF
ACWX
|
+$96.6M |
| 4 |
Amazon
AMZN
|
+$63.7M |
| 5 |
Prologis
PLD
|
+$47.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TWTR
Twitter, Inc.
TWTR
|
+$56.3M |
| 2 |
DRE
Duke Realty Corp.
DRE
|
+$36M |
| 3 |
Y
Alleghany Corp
Y
|
+$33M |
| 4 |
CTXS
Citrix Systems Inc
CTXS
|
+$26.6M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$20.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.05% |
| 2 | Healthcare | 14.94% |
| 3 | Financials | 14.18% |
| 4 | Consumer Discretionary | 10% |
| 5 | Industrials | 9.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLNA
1926
Filana Therapeutics
FLNA
$48.1M
| $1.53M | ﹤0.01% |
51,772
+365
| +0.7% | +$13.1K |
|
1927
Kymera Therapeutics
KYMR
$8.94B
| $1.53M | ﹤0.01% |
61,220
+993
| +2% | +$26.5K |
|
|
SPNS
1928
DELISTED
Sapiens International
SPNS
| $1.52M | ﹤0.01% |
82,290
+1,786
| +2% | +$33.6K |
|
|
SUMO
1929
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $1.52M | ﹤0.01% |
187,405
+41,835
| +29% | +$319K |
|
|
CVGW
1930
DELISTED
Calavo Growers
CVGW
| $1.52M | ﹤0.01% |
51,590
+919
| +2% | +$30.8K |
|
1931
Clean Energy Fuels
CLNE
$346M
| $1.51M | ﹤0.01% |
291,278
-567
| -0.2% | -$3.48K |
|
|
PFC
1932
DELISTED
Premier Financial Corp. Common Stock
PFC
| $1.51M | ﹤0.01% |
56,089
+1,652
| +3% | +$46.2K |
|
1933
Corsair Gaming
CRSR
$1.55B
| $1.51M | ﹤0.01% |
111,376
+2,162
| +2% | +$31.4K |
|
1934
Enterprise Products Partners
EPD
$81.7B
| $1.51M | ﹤0.01% |
62,605
+7,100
| +13% | +$175K |
|
|
SWTX
1935
DELISTED
SpringWorks Therapeutics
SWTX
| $1.51M | ﹤0.01% |
58,053
+4,939
| +9% | +$122K |
|
1936
BioLife Solutions
BLFS
$1.7B
| $1.5M | ﹤0.01% |
82,631
+4,039
| +5% | +$83.4K |
|
1937
Iovance Biotherapeutics
IOVA
$2.87B
| $1.5M | ﹤0.01% |
234,677
-2,452
| -1% | -$19.1K |
|
1938
Credo Technology Group
CRDO
$46.6B
| $1.5M | ﹤0.01% |
112,401
+13,728
| +14% | +$182K |
|
|
CIR
1939
DELISTED
CIRCOR International, Inc
CIR
| $1.49M | ﹤0.01% |
62,301
+1,630
| +3% | +$36.5K |
|
1940
Peoples Bancorp
PEBO
$1.47B
| $1.49M | ﹤0.01% |
52,799
+759
| +1% | +$22.3K |
|
1941
ATN International
ATNI
$492M
| $1.48M | ﹤0.01% |
32,654
-1,695
| -5% | -$74.1K |
|
|
RETA
1942
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.48M | ﹤0.01% |
38,952
+840
| +2% | +$28.9K |
|
1943
QuantumScape Corp
QS
$3.74B
| $1.47M | ﹤0.01% |
259,778
+7,268
| +3% | +$53.8K |
|
1944
iShares Russell Mid-Cap ETF
IWR
$57.5B
| $1.47M | ﹤0.01% |
21,753
-29,480
| -58% | -$1.99M |
|
1945
Hillman Solutions
HLMN
$1.79B
| $1.46M | ﹤0.01% |
202,838
+1,330
| +0.7% | +$10K |
|
1946
Energy Recovery
ERII
$443M
| $1.46M | ﹤0.01% |
71,306
+1,749
| +3% | +$38.3K |
|
1947
Cytek Biosciences
CTKB
$546M
| $1.46M | ﹤0.01% |
142,563
+1,845
| +1% | +$24.8K |
|
1948
Crinetics Pharmaceuticals
CRNX
$8.92B
| $1.45M | ﹤0.01% |
78,988
-7
| -0% | -$123 |
|
1949
Coeur Mining
CDE
$17.9B
| $1.44M | ﹤0.01% |
429,112
-1,032
| -0.2% | -$3.67K |
|
1950
Nicolet Bankshares
NIC
$3.62B
| $1.44M | ﹤0.01% |
18,045
+99
| +0.6% | +$7.71K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2022 Portfolio in Review
As of Q4 2022, RhumbLine Advisers held 3,107 positions worth $74.4B, up 11% from $67.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
RhumbLine Advisers deployed $2.46B of net new capital in Q4 2022, opening 25 new positions and adding to 2,535 existing holdings. Its largest new stake was iShares MSCI ACWI ex US ETF: 2,203,118 shares worth $100M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Steel Dynamics, an estimated $18.8M trimmed.
- RhumbLine Advisers's largest Q4 2022 buy was iShares MSCI ACWI ex US ETF: 2,203,118 shares worth $100M.
- RhumbLine Advisers added most to Microsoft in Q4 2022, an estimated $141M increase.
- RhumbLine Advisers's biggest Q4 2022 reduction was Steel Dynamics, cutting an estimated $18.8M.
- RhumbLine Advisers fully exited Twitter, Inc. in Q4 2022, selling an estimated $56.3M.
- RhumbLine Advisers's ten largest holdings make up 19% of its $74.4B portfolio in Q4 2022.
- RhumbLine Advisers opened 25 new positions and closed 97 in Q4 2022.
- RhumbLine Advisers's portfolio value rose 11% quarter-over-quarter to $74.4B.
Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.